Lindus Health, a London startup backed by Peter Thiel, has raised $55 million in a Series B funding round. The company aims to overhaul the clinical trial industry by leveraging artificial intelligence to automate and streamline the trial process. With its comprehensive platform, Lindus positions itself as an 'anti-CRO,' offering tools that help design protocols and manage every stage of clinical trials efficiently. The CRO market is expanding rapidly, projected to grow from $82 billion to $130 billion by 2030, highlighting the need for innovative solutions like Lindus Health's app.
Lindus Health aims to revolutionize the clinical trial industry with its automated platform, providing a streamlined process for drug discovery and development.
The CRO market was valued at $82 billion last year, with projections to grow to $130 billion by the decade's end, indicating significant demand in this sector.
Collection
[
|
...
]